HZ1 showed strong tumor-suppressing effect with IC50 at nanomolar range and the potential to overcome resistance to CDK4/6 inhibitor, and manifested satisfactory tumor clearance in laboratory animals and patient-derived samples. The gene discussed is CDK4; the disease is neoplasm.